Compare TMP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMP | ERAS |
|---|---|---|
| Founded | 1836 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1996 | 2021 |
| Metric | TMP | ERAS |
|---|---|---|
| Price | $75.92 | $14.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $74.00 | $11.38 |
| AVG Volume (30 Days) | 46.0K | ★ 4.1M |
| Earning Date | 04-24-2026 | 03-12-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ 126.16 | 36.23 |
| EPS | ★ 11.24 | N/A |
| Revenue | ★ $75,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.94 | N/A |
| P/E Ratio | $6.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $54.16 | $1.01 |
| 52 Week High | $86.95 | $16.14 |
| Indicator | TMP | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 55.80 |
| Support Level | $72.14 | $1.50 |
| Resistance Level | $77.33 | $16.14 |
| Average True Range (ATR) | 1.97 | 1.09 |
| MACD | -0.03 | -0.23 |
| Stochastic Oscillator | 63.80 | 43.72 |
Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.